<DOC>
	<DOCNO>NCT00002802</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy bone marrow transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Radiation therapy use high-energy x-rays damage tumor cell . It yet know treatment regimen effective treat patient different stage risk factor neuroblastoma . PURPOSE : Phase III trial study effectiveness therapy base stage disease risk assessment treat child neuroblastoma .</brief_summary>
	<brief_title>Therapy Based Stage Disease Risk Assessment Treating Children With Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : I . Increase survival rate duration survival child adolescent neuroblastoma use stage- risk group-appropriate therapy . II . Determine whether use cisplatin/etoposide/vindesine vincristine/dacarbazine/ifosfamide/doxorubicin instead cisplatin/teniposide vincristine/dacarbazine/cyclophosphamide/doxorubicin improve remission rate lessens toxicity patient stage 3C , 3D , 4 neuroblastoma . III . Determine whether local radiotherapy primary tumor bone metastasis improve local tumor control patient . IV . Compare efficacy survival associate short-term , high-dose conditioning chemotherapy plus autologous bone marrow transplantation vs. long-term , low-dose cytostatic chemotherapy consolidation therapy patient . V. Determine whether early use low-dose doxorubicin/vincristine plus hepatic irradiation slow disease progression patient stage 4S-C neuroblastoma . VI . Determine whether 4 course chemotherapy reduces occurrence local systemic relapse patient stag 2 , 3A , 3B neuroblastoma . VII . Determine whether serum tumor marker ( LDH , catecholamine metabolite , neuron-specific enolase ) predictive remission behavior . OUTLINE : Patients stag accord International Neuroblastoma Staging System define progressively less favorable risk group base age diagnosis , serum LDH , tumor resectability ( risk group A , B , C , D , represent presence 0 , 1 , 2 , 3 risk factor , respectively ) . Patients unable resected entry incomplete resection re-evaluated 4-month interval appropriateness tumor resection . STAGE 1 PATIENTS Patients undergo complete primary tumor resection therapy . STAGES 2 , 3A , AND 3B PATIENTS Patients undergo primary tumor resection , follow cisplatin , etoposide , vindesine ( PEV ) alternate monthly vincristine , dacarbazine , ifosfamide , doxorubicin ( VDIA ) . Patients complete remission ( CR ) discontinue therapy , less CR receive additional therapy outline stage 3C , 3D , 4 patient , except patient eligible bone marrow transplantation . STAGES 3C , 3D , AND 4 PATIENTS Patients receive PEV VDIA , radiotherapy site metastases third fourth course , follow autologous bone marrow collect . Following marrow harvest , patient receive 4 alternating course PEV/VDIA ; response progressive disease sixth chemotherapy course refer therapy . Patients complete PEV/VDIA receive 3 week radiotherapy primary tumor bed residual tumor . Stage 4 patient complete good partial remission sufficient harvest marrow undergo ABMT follow radiotherapy . Myeloablation consist high-dose MIBG radioisotope therapy follow high-dose melphalan , etoposide , carboplatin . All patient refuse ABMT receive 1 year alternating , low-dose chemotherapy course , begin concurrently initiation radiotherapy . One regimen consist oral melphalan/etoposide 5 day regimen consist intravenous vincristine 1 day oral cyclophosphamide 7 day . Therapy continue 1 year . STAGE 4S PATIENTS Patients risk group 4S-A 4S-B receive therapy . Patients group 4S-C receive 4-8 weekly injection doxorubicin vincristine ( AV ) . Patients tumor progression may receive low-dose radiotherapy . Primary tumor resection may delay 8 month diagnosis patient . Use G-CSF allow recommend . PROJECTED ACCRUAL : Approximately 500 patient accrue multicenter study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Neuroblastoma diagnosis base one following : Histologic confirmation Cytologic confirmation bone marrow elevate catecholamine metabolite Typical tumor appearance CT , MRI , ultrasound : Unequivocal MIBG uptake tumor Elevated catecholamine serum urine No primitive neuroectodermal tumor primary intracerebral neuroblastoma Such patient refer protocol GERHIT90 PATIENT CHARACTERISTICS : Age : Under 21 Other : No serious cerebral trouble No severe concomitant disease , e.g . : No severe congenital malformation No severe organ function abnormality PRIOR CONCURRENT THERAPY : No prior cytostatic therapy ( e.g. , Wilms ' tumor ) No concurrent therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
</DOC>